| Oct 24 |
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
|
| Oct 18 |
Marinus reports Phase III RAISE trial results for ganaxolone in RSE treatment
|
| Oct 17 |
Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
|
| Oct 15 |
Health Care Roundup: Market Talk
|
| Oct 15 |
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
|
| Oct 9 |
Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
|
| Oct 8 |
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
|
| Oct 3 |
Here’s Why PGIM Jennison Health Sciences Fund Reduced its Position in Marinus Pharmaceuticals (MRNS)
|
| Sep 26 |
Great week for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) institutional investors after losing 78% over the previous year
|
| Sep 20 |
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
|
